ADDITIONAL QUESTIONS KORRAL
+372 5592 6321
Order now
Advanced non-invasive cancer diagnostics

Services

We offer two types of liquid biopsy tests.

Trucheck Intelli

Trucheck™ Intelli is designed to detect more than 70 types of cancer, which together account for approximately 81% of cancer cases and 84% of cancer-related deaths in Europe.

1890€

The service price includes the test, interpretation of the results, and, if necessary, recommendations for further examinations and treatment planning.

Order now

Trucheck FemmeSafe

Trucheck™ FemmeSafe is a blood-based test designed to detect circulating tumor cells (CTCs) associated with breast, ovarian, cervical, and uterine (endometrial) cancers.

1690€

The service price includes the test, interpretation of the results, and, if necessary, recommendations for further examinations and treatment planning.

Order now

Trucheck Intelli

Trucheck™ Intelli is designed to detect more than 70 types of cancer, which together account for approximately 81% of cancer cases and 84% of cancer-related deaths in Europe.

1890€

The service price includes the test, interpretation of the results, and, if necessary, recommendations for further examinations and treatment planning.

Order now

Trucheck FemmeSafe

Trucheck™ FemmeSafe is a blood-based test designed to detect circulating tumor cells (CTCs) associated with breast, ovarian, cervical, and uterine (endometrial) cancers.

1690€

The service price includes the test, interpretation of the results, and, if necessary, recommendations for further examinations and treatment planning.

Order now

Trucheck

Trucheck™ is a new blood-based test for multi-cancer detection.

About Trucheck™

Approximately 4.4 million new cancer cases are diagnosed in Europe each year, and around 2 million cancer-related deaths occur annually. Unfortunately, some cancers are detected at a late stage, which may require more intensive and expensive treatment and can be associated with a higher risk of side effects.

Early and localized cancer detection is important for enabling less intensive treatment, reducing treatment-related toxicity and improving survival outcomes.

Trucheck™ is the result of years of international collaboration and innovation and has been developed, tested and validated using data from more than 40,000 participants.

Trucheck™ technology

  • Trucheck™ detects circulating tumor cellsCTCand collections of these cells that are released of benign tumors, but not from non-cancerous (normal, benign, or inflammatory) tissue. Therefore, CTCs are found in the blood of cancer patients, but do not occur in the blood of healthy individuals.
  • Trucheck™ Intelli is able to distinguish approximately 70 different solid tumors that form approximately 81% of all cancer cases and 84% of all cancer-related deaths in Europe.
  • Clinical trials have shown that Trucheck™ sensitivity in cancer detection across all stages and types is 88%. Additionally, Trucheck™ Intelli accuracy in determining the origin of tumor tissue or organ 96%.
  • Real-world data show sensitivity ranging from 65% to 89%, depending on the tumor type, and specificity ranging from 96% to 99%.
  • Trucheck™ is designed to detect cancer across different stages of the disease, including early-stage cancer.

Important publications

Akolkar D. and al.

Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer (International Journal of Cancer, 2020)

Population - Cancers: 5,509 (Retrospective) • Asymptomatic: 10,625 (Prospective)


Parameters – Analyte: C-ETACs, CTCs • Proof of Concept Study


Performance Characteristics – Specificity: 96.4% (Asymptomatic) • Sensitivity: 89.5% (Retrospective)

Renade A. and al.

Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One Year Cancer Risk. (AACR, 2021)

Population – Cancers: 5,509 (Retrospective) & 4,419 (P) • Benign: 324 (Prospective) • Asymptomatic: 10,625 (Prospective)


Parameters – Analyte: C-ETACs, CTCs • Assessment: Colony Detection Assay • Proof of Concept Follow-up Study


Performance Characteristics – Specificity: 97.5% (Benign) & 95.6% (Asymptomatic) • Sensitivity: 93.0% (Retrospective) & 93.0% (Prospective)

Gaya A. and al.

Evaluation of circulating tumor cell clusters for pan-cancer non-invasive diagnostic triaging. (ACS Journal, 2021)

Population – Cancers: 9,416 (Retrospective) & 6,025 (Prospective) • Benign: 700 • Asymptomatic: 13,919 (Prospective)


Parameters – Analyte: C-ETACs, CTCs • Assessment: Colony Detection Assay • Clinical Validation Study


Performance Characteristics – Specificity: 99.3% (Benign) & 100.0% (Asymptomatic) • Sensitivity: 85.2% (Retrospective) & 86.7% (Prospective)

Crook T. and al.

Accurate screening for early-stage breast cancer through the detection and profiling of circulating tumor cells. (Cancers, 2022)

Case-Control Study
Population - Breast Cancer Cases: 548 • Asymptomatic: 9,632

Parameter – Analyte: Breast-Adenocarcinoma-Associated CTCs

Performance Characteristics – Specificity: 100.0% • Sensitivity: 92.07%

Prospective clinical study
Population – Breast Cancer Cases: 112 • Benign Breast Conditions: 29

Parameter – Analyte: Breast-Adenocarcinoma-Associated CTCs

Performance Characteristics – Specificity: 93.1% • Sensitivity: 94.64%

Trucheck™ is primarily recommended:

For individuals with a family history of cancer.

For individuals who wish to add this test to their annual health check-up.

For individuals with an increased risk of cancer.

Benefits

Unlike screening for a single type of cancer at a time, Trucheck™ can detect multiple types of cancer through a simple blood test, including tumors that may go undetected using conventional screening methods.

Early detection of cancer is associated with a greater likelihood of successful treatment and improved survival outcomes. Trucheck™ Intelli analyzes circulating tumor cells (CTCs) to identify molecular characteristics associated with the tumor from which these cells originate. This can help determine the likely tissue or organ of origin and guide further diagnostic investigations.

Trucheck™ is an advanced blood-based cancer detection method that combines high sensitivity and specificity and is designed to detect cancer at different stages, including early-stage cancer in asymptomatic individuals.

Method

CTC enrichment:

Conventional CTC (circulating tumor cell) enrichment methods are based either on immunoaffinity capture (magnetic methods) or on separation by size and charge (microfluidic devices).

  • Immunoaffinity-based enrichment This is limited by cancer cells expressing low amounts of epitopes, or by cell clusters where some cells do not express epitopes at all. This reduces sensitivity and also randomly enriches non-malignant cells that express the same epitope, thereby reducing specificity.
  • Separation based on size or charge fails to effectively capture CTCs that fall outside the device's operating range, and may also collect non-malignant cells that meet the separation parameters.

Unlike conventional enrichment methods, Trucheck™ uses an Epigenetically Activated Medium (EAM) to enrich CTCs based on the characteristic ability of cancer cells to evade apoptosis. When isolated peripheral blood mononuclear cells (PBMCs) are exposed to EAM, non-malignant cells undergo apoptosis through their normal cellular mechanisms, while malignant cells, including CTCs, survive.

Tissue-specific and organ-specific markers:

Conventional CTC-based technologies detecting CTCs EpCAM+, PanCK+ Yes CD45- based on cells. However, this approach overlooks non-carcinomatous cancer forms where these markers are missing.

Additionally Trucheck™ is not limited to only distinguishing between malignant and non-malignant cells through negative enrichment, but also contains evaluation of tissue- and organ-specific markers. These markers are known to be expressed in cancer cells, but are mostly absent in normal cells.

Trucheck™ includes markers that cover various carcinoma subtypes no specific markers either for gliomas, sarcomas, and neuroendocrine tumors.

Microscopic images of stained cells from a cancer patient sample.

Trucheck™ uses multiplex fluorescence immunocytochemistry (ICC), to evaluate multiple markers within a single analysis cycle using antibodies conjugated with unique fluorophores.

Sample Collection

Requirements:

Blood draw:
3 EDTA tube (with a small basket) –
2 × 10 ml ja 1 × 6 ml – Total: 26 ml

The order of blood collection must not be changed. Blood samples must be collected by a qualified phlebotomist under medical supervision. Samples must be transported at +2 °C to +6 °C in the container provided by DCG.

Precautions:

  • The blood test must be collected after 6-hour fasting. Drinking water is allowed.
  • All four pages of the application form must be read and completed by both the patient and the physician. Please ensure that the location, date, and signature are provided in all required fields.

Estimated time of results

10 days from receipt of the sample

Order now

Select the blood test service provider